Close Menu

Breaking News

The oral MET inhibitor, marketed as Tabrecta, is for patients whose tumors have a mutation that leads to MET exon 14 skipping as detected by a Foundation Medicine test.

The group said the recommendations aim to standardize and improve warfarin response genotyping assays.

The deal marks the 10th distribution agreement Australia-based Sienna has signed for its test, including one covering Finland earlier this year.

The company had received CE marking for the test in April, allowing for its use as a clinical diagnostic test in Europe.

The company will use the funds to increase manufacturing, supply, and testing capacity for the SARS-CoV-2 test it launched in March.

The company posted Q1 revenues of $15.7 million, up from $12.3 million in Q1 2019 and above the consensus Wall Street estimate of $13.3 million.

The firm reported total revenues of $164 million, which was below the consensus Wall Street estimate of $167.2 million.

The San Francisco-based firm reported $64.2 million in revenues, up from $40.6 million a year ago and beating the average Wall Street estimate of $59.4 million.

In the quarter T2 signed a licensing agreement for SARS-CoV-2 assay development and a purchasing agreement with Vizient.

The company's Diagnostics segment was down 2 percent year over year, while its Discovery & Analytical Solutions segment grew 2 percent.

NG Biotech's COVID-19 NG-Test IgG-IgM test detects and differentiates the presence of isotypes IgG and IgG antibodies to SARS-CoV-2.

Both RT-PCR tests are designed to detect SARS-CoV-2 nucleic acid in nasal swabs, although Sansure's test can be used with other respiratory specimens.

The added funds will be used by Tangen to develop a molecular diagnostic platform to detect anthrax in the bloodstream and develop infectious disease tests.

The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.

The test will be included in the World Health Organizations list of prequalified in vitro diagnostics and UN agencies will be able to procure it.

The drugmaker will cover the cost of testing for up to 500 patients in the US with MSI-high colorectal cancer or RAI-refractory differentiated thyroid cancer.

Asia revenue fell 22 percent year over year, primarily due to a slowdown of testing in China as a result of the COVID-19 pandemic, the company said.

SG Blocks said it intends to create SARS-CoV-2 testing facilities using its expertise in building structures from maritime-grade shipping containers.

The firm said it anticipates introducing an antibody test for its high-throughput analyzers that will detect an immune response to the coronavirus.

The firms have already completed proof-of-concept studies for their semiconductor biosensor chips and Roswell plans to have the initial chips by 2021.

The Euroimmun's Anti-SARS-CoV-2 ELISA test is the first serology test whose results were independently validated by the federal government.

The company's revenue growth was driven by increasing sales of its ePlex molecular diagnostics analyzer, which now has a SARS-CoV-2 test.

The firm's first quarter molecular diagnostics revenues were up 28 percent over Q1 2019 to $45.2 million.

Fulgent saw a 75 percent increase year over year in billable tests, leading to revenues of $7.8 million. It also withdrew its 2020 full-year revenue guidance.

Although the firm said it refocused its business strategy to address the need for COVID-19 tests in Q1, product sales fell 14 percent year over year.

Pages